This is a working overview of research compound, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
==== Marine algae ==== The factors affecting δD of algal lipids are: δD of water, algal species (up to 160%), lipid type (up to 170%), salinity (+0.9±0.2% per PSU), growth rate (0 ~ −30% per day) and temperature (−2 ~ −8% per °C). In a study by Zhang et al. (2009), the δDs of fatty acids in Thalassiosira pseudonana chemostat cultures were −197.3‰, −211.2‰ and −208.0‰ for C14, C16 and C18 fatty acids respectively. The δD of C16 fatty acid in the algae A. e. unicocca at 25°C, was determined using the empirical equation y = 0.890x − 91.730, where x is the δD of water at harvest. For another algal species, B. v. aureus, the equation was y = 0.869x − 74.651. The degree of D/H fractionation in most algal lipids increases with increasing temperature and decreases with increasing salinity. The growth rates have different impacts on the D/H fractionation depending on the species types.
The cephalic phase: Thirty percent of the total gastric acid secretions to be produced is stimulated by anticipation of eating and the smell or taste of food. This signalling occurs from higher centres in the brain through the vagus nerve (Cranial Nerve X). It activates parietal cells to release acid and ECL cells to release histamine. The vagus nerve (CN X) also releases gastrin releasing peptide onto G cells. Finally, it also inhibits somatostatin release from D cells. The gastric phase: About sixty percent of the total acid for a meal is secreted in this phase. Acid secretion is stimulated by distension of the stomach and by amino acids present in the food. The intestinal phase: The remaining 10% of acid is secreted when chyme enters the small intestine, and is stimulated by small intestine distension and by amino acids. The duodenal cells release entero-oxyntin which acts on parietal cells without affecting gastrin.
== Selected-reaction monitoring chromatogram (SRM, MRM) == The selected-reaction monitoring (SRM) experiment is very similar to the SIM experiment except that tandem mass spectrometry is used and a specific product ion of a specific parent ion is detected. The mass of the parent analyte is first selected while other ions are filtered away. The parent analyte ion is then fragmented in the gas phase and a specific fragment ion is monitored. This experiment has very high specificity because the SRM chromatogram represents only ions of a particular mass that fragment in a manner that produce a very specific product mass. This type of experiment can only be performed using tandem mass spectrometry. The technology progress in the MS/MS area lead to the development of MRM, Multiple Reaction Monitoring, which allows simultaneous detection of several coeluting analytes with different parent and/or product ions.
Sources: en.wikipedia.org
== Awards received while alive == In 1919, she was awarded the Notable Service Medal by President Herbert Hoover for her work in refrigeration. In 1940, she became the second recipient of the Garvan–Olin Medal, then called the Francis P. Garvan Medal, from the American Chemical Society.
However, there is significant charge transfer between the two materials and, in some cases, hybridization between the d-orbitals of the substrate atoms and π orbitals of graphene, which significantly alter the electronic structure compared to that of free-standing graphene. Boehm et al. coined the term "graphene" for the hypothetical single-layer structure in 1986. The term was used again in 1987 to describe single sheets of graphite as a constituent of graphite intercalation compounds, which can be seen as crystalline salts of the intercalant and graphene. It was also used in the descriptions of carbon nanotubes by R. Saito and Mildred and Gene Dresselhaus in 1992, and in the description of polycyclic aromatic hydrocarbons in 2000 by S. Wang and others. Efforts to make thin films of graphite by mechanical exfoliation started in 1990. Initial attempts employed exfoliation techniques similar to the drawing method. Multilayer samples down to 10 nm in thickness were obtained. In 2002, Robert B. Rutherford and Richard L. Dudman filed for a patent in the US on a method to produce graphene by repeatedly peeling off layers from a graphite flake adhered to a substrate, achieving a graphite thickness of 0.00001 inches (0.00025 millimetres). The key to success was the ability to quickly and efficiently identify graphene flakes on the substrate using optical microscopy, which provided a small but visible contrast between the graphene and the substrate. Another U.S. patent was filed in the same year by Bor Z. Jang and Wen C.
== Education == Frank completed her M.D. and Ph.D. in biochemistry at the University of Pennsylvania. She completed a clinical pathology residency at the Brigham and Women's Hospital. During her postdoctoral research fellowship in immunology, she focused on V(D)J recombination in developing lymphocytes in the Howard Hughes Medical Institute laboratory of Frederick Alt at the Boston Children's Hospital. As a faculty member, her studies included DNA repair mechanisms relevant to both cancer and immunology, followed by microbiological investigations of Staphylococcus aureus and enterobacteriaceae.
=== FastGC === Gas chromatography (GC) in combination with mass spectrometry (GC-MS) is capable of separating isomeric compounds. Although GC has been successfully coupled to PTR-MS in the past, this approach annihilates the real-time capability of the PTR-MS technology, because a single GC analysis run typically takes between 30 min and 1 h. Thus, state-of-the-art GC add-ons for PTR-MS are based on fastGC technology. Materic et al. utilized an early version of a commercially available fastGC addon in order to distinguish various monoterpene isomers. Within a fastGC run of about 70 s they were able to separate and identify: alpha-pinene, beta-pinene, camphene, myrcene, 3-carene and limonene in a standard mixture, Norway spruce, Scots pine and black pine samples, respectively. Particularly, if the operation mode of a PTR-MS instrument equipped with fastGC is continuously switched between fastGC and direct injection (dependent on the application, e.g. a loop sequence of one fastGC run followed by 10 min of direct injection measurement), real-time capability is preserved, while at the same time valuable information on substance identification and isomer separation is acquired.
Sources: en.wikipedia.org
Their first son Prince Aegon was born in 120 AC, while their second son was born in 122 AC and named after Viserys. In 126 AC, Rhaenyra requested that Luke be recognized as the heir to Driftmark, which several members of House Velaryon protested under the accusation that he was not Laenor's son. As Viserys angrily ordered their tongues to be cut out, he slipped and cut his hand on the Iron Throne, a severe injury that gave him a fever from infection. Some maesters feared that he would die, but Viserys lived after two of his fingers were removed by Maester Gerardys, and he would never sit on the Iron Throne again. Gerardys was recommended by Rhaenyra as a replacement for the dead Grand Maester Mellos, while Alicent recommended Maester Alfador, her family's maester. Viserys decided to appoint neither man as Grand Maester and deferred to the Citadel to fill the office, who chose Maester Orwyle. As Viserys' health gradually weakened, Otto filled the small council with members loyal to the greens, including Lord Larys Strong, Ser Tyland Lannister, and Ser Jasper Wylde. Lord Commander of the Kingsguard Criston Cole was also an ardent supporter of Alicent, with Orwyle being politically neutral and Lord Lyman Beesbury opposing the greens. Viserys passed away in his sleep in 129 AC, having been discovered by a servant who informed Alicent of his status. In the interim, Alicent did not disclose Viserys' death to the public and summoned the small council to a secret meeting.
Gilbert's syndrome (GS) is a syndrome in which the liver of affected individuals processes bilirubin more slowly than the majority, resulting in higher levels in the blood. Many people never have symptoms. Occasionally jaundice (a yellowing of the skin or whites of the eyes) may occur. Gilbert syndrome is due to a genetic variant in the UGT1A1 gene, which results in decreased activity of the bilirubin uridine diphosphate glucuronosyltransferase (UGT1A1) enzyme. It is typically inherited in an autosomal recessive pattern and occasionally in an autosomal dominant pattern depending on the type of variant. Episodes of jaundice may be triggered by stress such as exercise, menstruation, or not eating. Diagnosis is based on elevated levels of unconjugated bilirubin in the blood without signs of liver problems or red blood cell breakdown. Typically, no treatment is needed. Phenobarbital aids in the conjugation of bilirubin and can be prescribed if jaundice becomes significant. Gilbert syndrome is associated with decreased cardiovascular health risks but increased risks of some cancers and gallstones. Gilbert syndrome affects about 5% of people in the United States. Males are more often diagnosed than females. It is often not noticed until late childhood to early adulthood. The condition was first described in 1901 by Augustin Nicolas Gilbert.
A few different types of mass fragmentation are collision-induced dissociation (CID) through collision with neutral molecule, surface-induced dissociation (SID) using fast moving ions collision with a solid surface, laser induced dissociation which uses laser to induce the ion formation, electron-capture dissociation (ECD) due to capturing of low energy electrons, electron-transfer dissociation (ETD) through electron transfer between ions, negative electron-transfer dissociation (NETD), electron-detachment dissociation (EDD), photodissociation, particularly infrared multiphoton dissociation (IRMPD) using IR radiation for the bombardment and blackbody infrared radiative dissociation (BIRD) which use IR radiation instead of laser, higher-energy C-trap dissociation (HCD), EISA, and charge remote fragmentation.
In 1805, American inventor Oliver Evans described a closed vapor-compression refrigeration cycle for the production of ice by ether under vacuum. In 1820, the British scientist Michael Faraday liquefied ammonia and other gases by using high pressures and low temperatures, and in 1834, an American expatriate in Great Britain, Jacob Perkins, built the first working vapor-compression refrigeration system. It was a closed-cycle device that could operate continuously. A similar attempt was made in 1842, by American physician, John Gorrie, who built a working prototype, but it was a commercial failure. American engineer Alexander Twining took out a British patent in 1850 for a vapor compression system that used ether. The first practical vapor compression refrigeration system was built by James Harrison, a Scotsman. His 1856 patent was for a vapor compression system using ether, alcohol or ammonia. He built a mechanical ice-making machine in 1851 on the banks of the Barwon River at Rocky Point in Geelong, Victoria, and his first commercial ice-making machine followed in 1854. Harrison also introduced commercial vapor-compression refrigeration to breweries and meat packing houses, and by 1861, a dozen of his systems were in operation. The first gas absorption refrigeration system (compressor-less and powered by a heat-source) was developed by Edward Toussaint of France in 1859 and patented in 1860. It used gaseous ammonia dissolved in water ("aqua ammonia").
They were supported by the 123rd Special Tactics Squadron, 173rd Airborne Brigade and several companies of 2nd Battalion, 14th Infantry Regiment, 10th Mountain Division. The original plan called for TF Viking to support the 4th Infantry Division advance from Turkey towards Baghdad but the mission was cancelled when Turkey denied staging rights to the US. Viking was assigned the task of keeping 13 Iraqi armoured and infantry divisions in the north from reinforcing Baghdad, the 10th SFG was to organise the Kurdish Peshmerga to support them. Just as in Afghanistan, SF were the first military units in Iraq after the initial entry of JSOC (Joint Special Operations Command) and the CIA. At H-Hour, Bravo and Charlie companies of 1st Battalion, 5th SFG, crossed the Kuwait border began carrying out operations in western Iraq – joining up with the British and Australian SAS and Delta Force elements to secure H-3 Air Base, as well as securing Ar Rutbah; the 5th SFG also carried out operations in support of forces moving on Karbala Nasiriyah and Al Diwaniyah. On 21 March, ODA 554 of Charlie Company, 2nd Battalion 5th SFG entered Iraq and began carrying out operations in southern Iraq – mainly supporting British forces in the seizure of Basra and surrounding locations, until relieved by G squadron, 22 SAS Regiment.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.